PEG in mRNA Vaccines

Of all approved COVID-19 vaccines in the market, the vaccines developed by BioNTech/Pfizer and Moderna represent a new class of vaccine products: they are composed of messenger ribonucleic acid (mRNA) strands encapsulated in lipid nanoparticles (LNPs).

The LNPs in mRNA covid-19 vaccines consist of four main components: a neutral phospholipid, cholesterol, a polyethylene-glycol (PEG)-lipid, and an ionizable cationic lipid, among them, PEG lipids can have multiple effects on the properties of lipid nanoparticles.

  1. Increase particle stability by decreasing particle aggregation;
  2. Prolong the blood circulation time of nanoparticles by reducing clearance mediated by the kidneys and the mononuclear phagocyte system (MPS);
  3. Conjugate specific ligands to the particle for targeted delivery.

Biopharma PEG is a dynamic science company dedicated to PEG derivatives. We are capable of supplying small to large quantities of a rich selection of PEG derivatives with GMP & non-GMP standards for your mRNA vaccine R&D.  We can produce and provide the following PEG products for your mRNA vaccines R&D.

1. Hou, X., Zaks, T., Langer, R. et al. Lipid nanoparticles for mRNA delivery. Nat Rev Mater 6, 1078–1094 (2021).
2. Schoenmaker, Linde, et al., mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability, International Journal of Pharmaceutics 601 (2021).